

PRESS RELEASE

Hansa Biopharma to host conference call to provide Year-end 2022 results and a Business Update

Lund, Sweden, January 20, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its Year-end Report 2022 at 8:00 CET on February 2, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 020 3936 2999

United States: +1 646 664 1960

Participant access code: 031372

The webcast will be available on <https://events.q4inc.com/attendee/195504216>

Financial calendar and events 2023

Feb 2, 2023	Interim Report for January-December 2022
Feb 9, 2023	Mid-cap event, Frankfurt
Feb 23, 2023	Erik Penser Healthcare Seminar, Stockholm
Mar 7, 2023	Redeye Healthcare Seminar: Commercialization, Stockholm
Mar 16, 2023	Carnegie Nordic Healthcare Seminar 2023, Stockholm
Mar 30, 2023	2022 Annual Report
April 4, 2023	Guggenheim Healthcare Talks Rare Disease Days
April 20, 2023	Interim Report for January-March 2023
April 20 2023	Redeye investor forum, Gothenburg
April 21 2023	Redeye lunch presentation, Stockholm
April 25 2023	Kempen Life Sciences Conference 2023, Amsterdam
May 11, 2023	Erik Penser Company Day, Malmö
May 11, 2023	Redeye investor forum, Malmö
May 25, 2023	Erik Penser Company Day, Stockholm
June 14, 2023	Annual General Meeting 2023
July 20, 2023	Half-year Report for January-June 2023
Oct 19, 2023	Interim Report for January-September 2023

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, *VP Global Corporate Affairs*

M: +1 (484) 319 2802

E: stephanie.kenney@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.